Publication | Open Access

1313MO Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy

Bispecific AntibodyMedicineImmunologyTumor ImmunityImmune Checkpoint InhibitorImmunotherapeuticsPreliminary EfficacyCancer TreatmentImmunotherapyOncologyRadiation OncologyPrevious Anti-pd-Lung Cancer